Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
Status:
Completed
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate Halobetasol Propionate (HBP) foam, 0.05% in subjects
aged 12 through less than 18 years with plaque psoriasis in order to check the safety, the
potential to suppress the adrenal glands and the degree to which the drug is absorbed into
the bloodstream.